Covered recipient · General Payments record
KATHERINE ELIZABETH SCHULZ
Physician Assistants & Advanced Practice Nursing Providers Physician Assistant Medical
General Payments · PY2021–2024
$3,569.96
- Reported across 211 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $332.43 | 18 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $69.96 | 4 |
| ABBVIE INC. | $61.05 | 3 |
| Lilly USA, LLC | $49.09 | 3 |
| Amgen Inc. | $38.29 | 2 |
| GlaxoSmithKline, LLC. | $34.64 | 2 |
| Astellas Pharma US Inc | $30.56 | 1 |
| Daiichi Sankyo Inc. | $16.82 | 1 |
| Acerta Pharma LLC | $16.39 | 1 |
| PFIZER INC. | $15.63 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (18)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $23.31 | 01/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108162717 | CMS |
| ABBVIE INC. | $19.01 | 03/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108162719 | CMS |
| ABBVIE INC. | $18.73 | 04/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1108162721 | CMS |
| Amgen Inc. | $19.20 | 03/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117678237 | CMS |
| Amgen Inc. | $19.09 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117678239 | CMS |
| Astellas Pharma US Inc | $30.56 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139469504 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.39 | 04/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104756430 | CMS |
| Daiichi Sankyo Inc. | $16.82 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089479747 | CMS |
| GlaxoSmithKline, LLC. | $19.42 | 01/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116489764 | CMS |
| GlaxoSmithKline, LLC. | $15.22 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116182616 | CMS |
| Lilly USA, LLC | $15.55 | 01/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135669396 | CMS |
| Lilly USA, LLC | $16.66 | 03/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135725771 | CMS |
| Lilly USA, LLC | $16.88 | 08/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135764231 | CMS |
| Novo Nordisk Inc | $13.30 | 03/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100592368 | CMS |
| Novo Nordisk Inc | $20.91 | 08/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100584166 | CMS |
| Novo Nordisk Inc | $19.71 | 10/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100534525 | CMS |
| Novo Nordisk Inc | $16.04 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1100474540 | CMS |
| PFIZER INC. | $15.63 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131939237 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.